{"id":55925,"date":"2016-03-14T18:45:06","date_gmt":"2016-03-14T18:45:06","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=55925"},"modified":"2016-03-14T18:45:06","modified_gmt":"2016-03-14T18:45:06","slug":"immune-therapeutics-inc-using-the-power-of-the-body-to-fight-cancer-and-aids-take-a-serious-look-at-imun","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/immune-therapeutics-inc-using-the-power-of-the-body-to-fight-cancer-and-aids-take-a-serious-look-at-imun_55925.html","title":{"rendered":"Immune Therapeutics, Inc. – Using the Power of the Body to Fight Cancer and AIDS. Take a Serious Look at IMUN."},"content":{"rendered":"
Each year, cancer costs the world more money than any other disease, according to the American Institute of Cancer Research (AICR). Cancer costs $895 billion annually. Comparatively, heart disease costs $753 billion. Nothing else comes close, with traffic accidents and diabetes each costing about $204 billion. The biggest financial impact is in terms of loss of life and productivity, in which cancer accounts for 1.5 percent of global gross domestic product (GDP) losses.<\/div>\n

EXPANDING IMMUNE STIMULATION TO REVELUTIONIZE THE FIGHT AGAINST CANCERS, AUTOIMMUNE AND INFECTIOUS DISEASES . . .<\/p>\n

IMUN HAS SIGNIFICANT UPSIDE!<\/p>\n

IMMUNE THERAPEUTICS, INC.
Ticker:  IMUN
STW Resources Holding Corp<\/p>\n

Web Site: ImmuneTherapeutics.com<\/p>\n

 
Who We Are:
Immune Therapeutics, Inc. (OTCQB: IMUN) is a biotechnology company applying its patented immunotherapy to combat chronic, life-threatening diseases that affect people around the world. Building on the power of the body’s natural immune system, the company’s pipeline of products and immunotherapy technologies are designed to enhance the treatment of cancer, infections such as HIV\/AIDS, chronic inflammatory diseases, and a variety of autoimmune diseases.<\/p>\n

Each year, cancer costs the world more money than any other disease, according to the American Institute of Cancer Research (AICR). Cancer costs $895 billion annually. Comparatively, heart disease costs $753 billion. Nothing else comes close, with traffic accidents and diabetes each costing about $204 billion. The biggest financial impact is in terms of loss of life and productivity, in which cancer accounts for 1.5 percent of global gross domestic product (GDP) losses.<\/p>\n

Immunotherapy, also called biologic therapy, is a type of cancer treatment designed to boost the body’s natural defenses to fight the cancer. It uses materials either made by the body or in a laboratory to improve, target, or restore immune system function.<\/p>\n

LATEST NEWS FROM IMUN:<\/p>\n

Immune Therapeutics, Inc., Appoints Two New Board Members
SeeThruEquity Initiates Coverage on Immune Therapeutics, Inc. with a Price Target of $0.61
Fidson Healthcare Plc and GB Pharma Holdings position pharmaceutical outreach into Nigeria and Beyond!
Immune Therapeutics, Inc., announced the completion of the bridging trial and submission of Lodonal(TM)
Immune Therapeutics Inc. To Present at JP Morgan Health Conference
IMMUNE THERAPEUTICS, INC.
Ticker: IMUN<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> PublicWire
Contact Person:<\/strong> Dave Donlin
Email:<\/strong> ddonlin@publicwire.com
Phone:<\/strong> 4074906635
Address:<\/strong>5850 TG Lee Blvd, Suite 300
City:<\/strong> Orlando
State:<\/strong> FL
Country:<\/strong> United States
Website:<\/strong> http:\/\/publicwire.com<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Each year, cancer costs the world more money than any other disease, according to the American Institute of Cancer Research (AICR). Cancer costs $895 billion annually. Comparatively, heart disease costs $753 billion. Nothing else comes close, with traffic accidents and … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-55925","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/55925","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=55925"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/55925\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=55925"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=55925"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=55925"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}